RxDoctor Payments DataLook up a doctor →

Jannah Thompson, MD

Urogynecology and Reconstructive Pelvic Surgery · Norton Shores, MINPI 1104089986

Payments from drug & device makers

$474,125in general payments, 2019–2025

Across 861 payments — averaging $550.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$377K
  • Boston Scientific$52K
  • Valencia Technologies Corporation$25K
  • Astellas Pharma US Inc$16K
  • Coloplast$1K
  • AbbVie$732
  • plus $2K from 26 others
$17,859in research payments, 2019–2025

Across 16 payments — averaging $1116.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$18K

What the payments were for

  • Consulting fees$55,83312%
  • Speaking & faculty fees$344,27073%
  • Travel & lodging$56,61812%
  • Food & beverage$17,0964%
  • Education$3080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$474,125 in reported general payments places this provider in the 95th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.

See all urogynecology and reconstructive pelvic surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$35,768
Medicare patients
125
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron167$105,976
GemtesaVibegron133$72,243
Estradiol272$20,032
Mirabegron ErMirabegron19$6,991
Solifenacin Succinate68$2,711
Methenamine Hippurate12$1,092
Cephalexin17$224
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$119
Gabapentin12$94
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$46
Ciprofloxacin Hcl11$27
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$23
Diazepam15$22
Tramadol Hcl23$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$16,070$105,976167 claims
Sumitomo Pharma America, Inc.Gemtesa$57$72,243133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.

Other urogynecology and reconstructive pelvic surgery in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →